Abstract
The JN1 variant harbors Leu455Ser and three mutations in non-spike
proteins contributing to increased transmissibility and immune escape
ability. Pseudovirus assays have shown that the infectivity of JN.1 is
significantly higher than its predecessor XBB.1.5 from omicron family
(1). JN.1 is about 3 to 5 times less susceptible to neutralizing
antibodies than the XBB.1.5 variant that is in the updated booster
raising concerns about its potential impact on public health (2)